|Bid||8.22 x 800|
|Ask||8.24 x 4000|
|Day's Range||8.17 - 8.57|
|52 Week Range||6.00 - 15.48|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $2.36 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
climbed 3.4% to $9.29 Thursday after Mizuho upgraded shares of the biopharmaceutical company to buy from neutral. Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Dermira, Inc. (NASDAQ:DERM) share price has gained some...
Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had a loss of $1.49 per share. The skin condition drug developer posted revenue of $2.5 million in the period, falling short of Street forecasts. Three ...
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you're interested in Dermira, Inc. (NASDAQ:DERM), then you might want to consider its beta (a measure of share price volat...
Why Dermira Stock Is Soaring More than 80% TodayShare price movements Today, Dermira (DERM) is trading close to $12.85, ~87.87% higher than its previous closing price, with a market capitalization of $292.48 million. The company is trading 114.19%
Boeing shares slipped more than 1.5 percent after The Wall Street Journal reported that federal prosecutors and the Department of Transportation are scrutinizing the development of the company's 737 Max jets. An Ethiopian Airlines flight involving the 737 Max 8 crashed on March 10. Facebook FB — Shares of the social media giant fell more than 3 percent after an analyst at Needham downgraded them to hold from buy.
Dermira news concerning results from a recent Phase 2b study has DERM stock flying high on Monday.Source: DermiraDermira (NASDAQ:DERM) is reporting that results from its Phase 2b study of using lebrikizumab to treat patients with atopic dermatitis were positive. Atopic dermatitis is a type of skin condition that's main symptom is a red, itchy rash.The Dermira news includes the results from the company testing out three different dosage amounts of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis. All three of these dosage levels were able to meet the primary endpoints of the Phase 2b study.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Phase 2b study of lebrikizumab involved 280 patients that were 18 or older. These patients were split into four groups for the study. Three of these groups received lebrikizumab at different amounts and the fourth was the placebo group. The treatment was also well tolerated with only mild to moderate adverse events."I have many patients for whom current therapies do not adequately address their needs," Emma Guttman-Yassky, M.D., Ph.D., and a leading investigator in the study, said in a statement . "These data show that lebrikizumab may offer a targeted, effective and well-tolerated therapeutic approach." * 7 Small-Cap Stocks That Make the Grade The positive Dermira news from the Phase 2b study results means that the company is planning to move forward with a Phase 3 study of the drug. It plans to start this next study quickly after getting in contact with U.S. regulators.DERM stock was up 83% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Dermira News: Why DERM Stock Is Skyrocketing Today appeared first on InvestorPlace.